T. Kuittinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
T. Kuittinen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Esa Jantunen
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
3 shared publications - Tapio Nousiainen
Department of Medicine, Kuopio University Hospital, P.O.B. 1777, 70211 Kuopio, Finland
3 shared publications E Jantunen
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2 shared publicationsE Mahlamäki
Department of Clinical Chemistry, Kuopio University Hospital, Kuopio, Finland
2 shared publicationsE. Jantunen
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2 shared publicationsT Nousiainen
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
2 shared publications
Latest Publications
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1) , 190-191
Secondary acute promyelocytic leukemia: An increasingly common entity
- 1 January 2007
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 48 (1) , 190-191
Secondary acute promyelocytic leukemia: An increasingly common entity
- 17 May 2006
- Published by Wiley in European Journal of Haematology
- Vol. 77 (2) , 120-127
Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
Objectives: Limited data are available on the cardiac effects of high‐dose cyclophosphamide (CY) in patients with non‐Hodgkin's lymphoma (NHL). We prospectively assessed the cardiac effects of high‐dose CY in 30 adult NHL patients receiving CY 6 g/m2 as part of BEAC high‐dose therapy (HDT).Methods: Radionuclide ventriculography (RVG) and plasma natriuretic peptide (NT‐proANP, NT‐proBNP) measurements were performed simultaneously prior to BEAC at baseline (d − 7), 12 days (d + 12) and 3 months (m + 3) after stem cell infusion (D0). In addition to these time points, natriuretic peptides were measured 2 days before (d − 2) and 1 week (d + 7) after stem cell infusion.Results: Left ventricular ejection fraction (LVEF) decreased from d − 7 (53% ± 2%) to d + 12 (49% ± 2%, P = 0.009). However, no significant change in cardiac diastolic function was observed. The LVEF returned towards baseline by m + 3. Plasma NT‐proANP and NT‐proBNP increased significantly from baseline (445 ± 65 pmol/L and 129 ± 33 pmol/L) to d − 2 (1127 ± 142 pmol/L, P < 0.001 and 624 ± 148 pmol/L, P < 0.001, respectively). Thereafter, they started to decrease, but on d + 7 NT‐proANP (404 ± 157 pmol/L, P = 0.048) and NT‐proBNP (648 ± 125 pmol/L, P = 0.015) were still significantly higher than at baseline. On d + 12 and m + 3 they no longer differed from baseline.Conclusions: Our findings suggest that high‐dose CY results in acute, subclinical systolic dysfunction in NHL patients previously treated with anthracyclines. Natriuretic peptides seem to be more sensitive than LVEF to reflect this transient cardiac effect. Serial measurements of natriuretic peptides might be a useful tool to assess cardiac effects of high‐dose CY.
- 17 May 2006
- Published by Wiley in European Journal of Haematology
- Vol. 77 (2) , 120-127
Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
Objectives: Limited data are available on the cardiac effects of high‐dose cyclophosphamide (CY) in patients with non‐Hodgkin's lymphoma (NHL). We prospectively assessed the cardiac effects of high‐dose CY in 30 adult NHL patients receiving CY 6 g/m2 as part of BEAC high‐dose therapy (HDT).Methods: Radionuclide ventriculography (RVG) and plasma natriuretic peptide (NT‐proANP, NT‐proBNP) measurements were performed simultaneously prior to BEAC at baseline (d − 7), 12 days (d + 12) and 3 months (m + 3) after stem cell infusion (D0). In addition to these time points, natriuretic peptides were measured 2 days before (d − 2) and 1 week (d + 7) after stem cell infusion.Results: Left ventricular ejection fraction (LVEF) decreased from d − 7 (53% ± 2%) to d + 12 (49% ± 2%, P = 0.009). However, no significant change in cardiac diastolic function was observed. The LVEF returned towards baseline by m + 3. Plasma NT‐proANP and NT‐proBNP increased significantly from baseline (445 ± 65 pmol/L and 129 ± 33 pmol/L) to d − 2 (1127 ± 142 pmol/L, P < 0.001 and 624 ± 148 pmol/L, P < 0.001, respectively). Thereafter, they started to decrease, but on d + 7 NT‐proANP (404 ± 157 pmol/L, P = 0.048) and NT‐proBNP (648 ± 125 pmol/L, P = 0.015) were still significantly higher than at baseline. On d + 12 and m + 3 they no longer differed from baseline.Conclusions: Our findings suggest that high‐dose CY results in acute, subclinical systolic dysfunction in NHL patients previously treated with anthracyclines. Natriuretic peptides seem to be more sensitive than LVEF to reflect this transient cardiac effect. Serial measurements of natriuretic peptides might be a useful tool to assess cardiac effects of high‐dose CY.
- Open Access
- 10 October 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (12) , 1077-1082
Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
- 10 October 2005
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 36 (12) , 1077-1082
Open AccessVery acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation
- 5 August 2005
- Published by Wiley in European Journal of Haematology
- Vol. 75 (3) , 199-205
Outcome of progressive disease after autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a nation‐wide survey
Abstract: Objectives: To analyse outcome and prognostic factors in non‐Hodgkin's lymphoma (NHL) patients who progress after autologous stem cell transplantation (ASCT). Patients: Altogether 115 consecutive NHL patients transplanted in 1991–2000 were studied. Histology included diffuse large B cell (n = 52), follicular (n = 26), mantle cell (n = 15), T cell (n = 16) and other subtypes (n = 6). The median time from ASCT to the progression was 7 months. Ninety‐six patients (83%) received salvage treatment. Results: Twenty‐four patients (25%) achieved complete remission and 30 (31%) partial remission. The median overall survival was 8 months (range 0–98+) and the projected 4‐year survival 21%. In multivariate analysis factors predicting treatment response after the progression included the use of rituximab (P = 0.036), histology other than diffuse large B cell (P = 0.001) and International Prognostic Index ≤2 at progression (P < 0.001). Normal lactate dehydrogenase (LDH) at progression (P = 0.002), response to salvage treatment (P < 0.001) and time from ASCT to progression ≥7 months (P = 0.022) were predictors for overall survival. Conclusions: Although the prognosis of patients who progress after ASCT is generally poor, many patients will respond to current therapies, and some may experience prolonged survival. Normal LDH at time of disease progression and longer time to progression after ASCT were the most powerful predictors for a promising outcome.
- 5 August 2005
- Published by Wiley in European Journal of Haematology
- Vol. 75 (3) , 199-205
Outcome of progressive disease after autologous stem cell transplantation in patients with non‐Hodgkin's lymphoma: a nation‐wide survey
Abstract: Objectives: To analyse outcome and prognostic factors in non‐Hodgkin's lymphoma (NHL) patients who progress after autologous stem cell transplantation (ASCT). Patients: Altogether 115 consecutive NHL patients transplanted in 1991–2000 were studied. Histology included diffuse large B cell (n = 52), follicular (n = 26), mantle cell (n = 15), T cell (n = 16) and other subtypes (n = 6). The median time from ASCT to the progression was 7 months. Ninety‐six patients (83%) received salvage treatment. Results: Twenty‐four patients (25%) achieved complete remission and 30 (31%) partial remission. The median overall survival was 8 months (range 0–98+) and the projected 4‐year survival 21%. In multivariate analysis factors predicting treatment response after the progression included the use of rituximab (P = 0.036), histology other than diffuse large B cell (P = 0.001) and International Prognostic Index ≤2 at progression (P < 0.001). Normal lactate dehydrogenase (LDH) at progression (P = 0.002), response to salvage treatment (P < 0.001) and time from ASCT to progression ≥7 months (P = 0.022) were predictors for overall survival. Conclusions: Although the prognosis of patients who progress after ASCT is generally poor, many patients will respond to current therapies, and some may experience prolonged survival. Normal LDH at time of disease progression and longer time to progression after ASCT were the most powerful predictors for a promising outcome.
- 22 March 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (9) , 907-912
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma
- 22 March 2004
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (9) , 907-912
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (10) , 1961-1965
A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients
To evaluate feasibility and potential efficacy of amifostine (AMI) in the prevention of toxicities associated with high-dose melphalan (MEL), ten myeloma patients received AMI 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2 followed by stem cell infusion (AMI group). Hematologic and extra-hematologic toxicities as well as the need for supportive care observed in the AMI group were compared with ten myeloma patients treated in an identical protocol but without AMI. Hypotension was the most important adverse event of AMI infusion. No differences were observed in the time of engraftment between the AMI group and the control group neither was there any difference in the need for supportive care. Oral mucositis grade >2 was observed in 30% of the patients in both groups. Diarrhea grade >2 occurred only in two AMI patients but in five control patients. AMI preceding high-dose MEL is feasible, although adverse events are observed in some patients. Whether AMI could reduce the gastrointestinal toxicity associated with high-dose MEL can be reliably assessed only in prospective randomized trials.
- 1 January 2002
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 43 (10) , 1961-1965
A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients
To evaluate feasibility and potential efficacy of amifostine (AMI) in the prevention of toxicities associated with high-dose melphalan (MEL), ten myeloma patients received AMI 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2 followed by stem cell infusion (AMI group). Hematologic and extra-hematologic toxicities as well as the need for supportive care observed in the AMI group were compared with ten myeloma patients treated in an identical protocol but without AMI. Hypotension was the most important adverse event of AMI infusion. No differences were observed in the time of engraftment between the AMI group and the control group neither was there any difference in the need for supportive care. Oral mucositis grade >2 was observed in 30% of the patients in both groups. Diarrhea grade >2 occurred only in two AMI patients but in five control patients. AMI preceding high-dose MEL is feasible, although adverse events are observed in some patients. Whether AMI could reduce the gastrointestinal toxicity associated with high-dose MEL can be reliably assessed only in prospective randomized trials.
- 1 January 2001
- Vol. 117 (11) , 1151-7
[Autologous stem cell transplantations in non-Hodgkin lymphomas].
- 1 January 2001
- Vol. 117 (11) , 1151-7
[Autologous stem cell transplantations in non-Hodgkin lymphomas].